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ABSTRACT
Objective: To investigate the ability of Magnetic resonance cholangiopancreatography (MRCP) to
exclude choledocholithiasis (CDL) in symptomatic patients.
Material and methods: Patients suspected of choledocholithiasis who underwent MRCP from 2008
through 2013 in a population based study at the National University Hospital of Iceland were retro-
spectively analysed, using ERCP and/or intraoperative cholangiography as a gold standard diagnosis
for CDL.
Results: Overall 920 patients [66% women, mean age 55 years (SD 21)] underwent MRCP. A total of
392 patients had a normal MRCP of which 71 underwent an ERCP investigation demonstrating a CBD
stone in 29 patients. A normal MRCP was found to have a 93% negative predictive value (NPV) and
89% probability of having no CBD stone demonstrated as well as no readmission due to gallstone dis-
ease within six months following MRCP. During a 6-month follow-up period of the 321 patients who
did not undergo an ERCP nine (2.8%) patients were readmitted with right upper quadrant pain and ele-
vated liver tests which later normalised with no CBD stone being demonstrated, three (0.9%) patients
were readmitted with presumed gallstone pancreatitis, two (0.6%) patients were readmitted with chole-
cystitis and two (0.6%) patients were lost to follow-up. Seven patients of those 321 underwent an intra-
operative cholangiography (IOC) and all were negative for CBD stones. For the sub-group requiring
ERCP following a normal MRCP the NPV was 63%.
Conclusion: Our results support the use of MRCP as a tool for exclusion of choledocholithiasis with the
potential to reduce the amount of unnecessary ERCP procedures.
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Introduction
Choledocholithiasis (CDL) is a common and potentially severe
form of gallstone disease. Around 10–25% of patients diag-
nosed with gallbladder stones have concomitant common
bile duct (CBD) stones, also known as choledocholithiasis
(CDL).[1,2] Magnetic resonance cholangiopancreatography
(MRCP), first described in 1991, is widely used as a non-inva-
sive imaging modality in the diagnosis of various pancreatico-
biliary conditions.[3,4] Despite the widespread use of MRCP in
many institutions, its role in CDL diagnosis has not been fully
established in clinical practise. If the results of MRCP were
found to be reliable it could reduce the amount of unneces-
sary ERCP procedures performed, thereby reducing complica-
tions associated with the procedure, such as post-ERCP
pancreatitis.[5–7]
Thus, the non-invasive nature of MRCP has attracted atten-
tion and been compared with more invasive diagnostic
approaches, such as endoscopic ultrasound (EUS) and endo-
scopic retrograde cholangiopancreatography (ERCP).[6,8–10]
MRCP has in some studies been shown to have a
diagnostic accuracy similar to EUS and ERCP [6,7,10–12] and
several studies have found MRCP to be a valuable imaging
modality when CDL is suspected, with relatively high
negative predictive value (NPV).[7–9,11] In contrast, other
studies found MRCP to be potentially unreliable with low NPV
[13,14] and/or relatively low sensitivity.[5,14,15] Furthermore,
many studies on the subject have been conducted on a lim-
ited number of patients.[5–9,11,13–21] Thus, the diagnostic
accuracy of MRCP in clinical practise is somewhat
controversial.
The aim of this study was to establish the diagnostic
accuracy of MRCP, in a large group of patients, especially
considering the ability to exclude CDL in symptomatic
patients. A secondary objective was to construct a plaus-
ible multivariate model based on the outcome of MRCP
and various clinical and/or biochemical findings, which
could be used as an aid along with MRCP in the exclu-
sion of CDL.
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Methods
Patient population
A retrospective study was undertaken on patients undergoing
MRCP suspected to have CDL from 2008 through 2013 in the
National University Hospital of Iceland. A computerised data-
base at the Department of Radiology was used to identify
MRCPs performed during the study period. Relevant clinical
data were obtained from medical records. Patients with indi-
cations other than CDL were excluded. Other exclusion crite-
ria were as follows: malignancy in or pertaining to the liver,
pancreas, biliary system and/or duodenum, ambulatory MRCP
investigations, former liver transplant, or major surgery per-
formed on the hepatobiliary system such as hepaticojejunos-
tomy, history of gastric bypass or Roux-en-Y anastomosis,
chronic pancreatitis, primary sclerosing cholangitis (PSC),
acute viral hepatitis, and Caroli syndrome. MRCPs in children
were also excluded.
The following clinical data were collected from medical
records: age, gender, length of hospital stay, and duration of
gallstone related symptoms. Also laboratory parameters:
serum bilirubin, white blood cell count, C-reactive protein
(CRP), alkaline phosphatase (ALP), c-glutamyl transpeptidase
(GGT), aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), amylase, and lipase levels were obtained. ERCP
was considered a gold standard diagnosis of CDL and the
results of an ERCP following MRCP were registered. If ERCP
was not performed, intraoperative cholangiography (IOC) was
considered a surrogate gold standard. For patients not under-
going ERCP or IOC, a follow-up time of 6 months was arbitrar-
ily defined and patients were considered stone-free at the
end of follow-up if they had not been admitted to hospital
with gallstone disease during the period. Furthermore,
records of previous or subsequent cholecystectomy were
obtained and the timeframe from MRCP to a therapeutic
ERCP recorded. It should be noted that ERCP is primarily used
as a therapeutic intervention at our institution and patients
did not undergo ERCP for diagnostic purposes only.
MRCP imaging
Outcomes of MRCP were recorded retrospectively and based
on the evaluation of the attending radiologist at the time of
the investigation. When according to the reports of the radi-
ologists the CDL diagnosis was somewhat uncertain, an expe-
rienced radiologist, among the authors (PH), re-evaluated the
MRCP images.
Variables detected and recorded on MRCP imaging
included CBD diameter, CBD stones, intra- and extrahepatic
bile duct dilatation, dilatation of the pancreatic duct, chole-
cystitis, pancreatitis, and gallbladder stones. A CBD above
7mm in diameter was considered dilated, but in patients
with a history of previous cholecystectomy a CBD above
10mm was considered dilated. An abnormal MRCP investiga-
tion was defined as a positive result for any of the variables
above, except for gallbladder stones and cholecystitis.
Magnetic resonance imaging (MRI) was performed on a 1.5
T Siemens Magnetom Avanto system (Siemens, Erlangen,
Germany). A series of T1- and T2-weigted images were taken,
with slice thickness 5–8mm. The MRCP slice thickness alone
was 1mm. The patients fasted for at least 4 h before the
MRCP. Neither spasmolytic agents nor oral contrast agents
were administered prior to or during the investigation.
Patients were imaged with a body phased-array receive coil.
Following are the sequences which were used after the local-
iser: T2 HASTE (half-Fourier acquisition single shot turbo spin
echo) coronal free breath, T2 HASTE axial free breath, T2 fat
saturated axial free breath, T1 in and out of phase axial
breath hold, T2 HASTE fat saturation thick slab breath hold,
and T2 coronal free breath.
Statistical analysis
Group analysis was performed using Student’s t-test and
Fischer’s exact test analysing numeric and dichotomous var-
iables, respectively. A logistic regression analysis was under-
taken, with a diagnosed stone, either on ERCP or IOC,
acting as the response variable. Positive predictive value
(PPV) was calculated for those who had a CBD stone on
MRCP and subsequently underwent an ERCP. Negative pre-
dictive value (NPV), on the other hand, was calculated for
those who presented with a normal MRCP, whether they
underwent an ERCP or not. In calculating the sensitivity
and specificity of MRCP, true positives, false positives, and
false negatives were all confirmed by ERCP or IOC whereas
all negative MRCPs for CBD stones were considered true
negatives whether that was confirmed by ERCP/IOC or not.
p< 0.05 was considered statistically significant. No correc-
tions were made for multiple testing. Statistical analysis
was performed using R version 3.0.2 and Microsoft Excel
2010. Statistical review of the study was performed by a
biomedical statistician.
Results
In total, 1655 patients underwent an MRCP investigation
between January 2008 and December 2013. Thereof 735
patients were excluded according to the above-mentioned
predetermined criteria (Figure 1). Overall 920 patients who
underwent MRCP due to suspected CDL were included in fur-
ther analysis, mean age 55 years (SD, 21 years), 607 patients
(66%) were women. Overall 392 patients had a normal MRCP
of which 71 underwent an ERCP investigation demonstrating
a CBD stone in 29 patients (Figure 1). A total of seven
patients underwent an intraoperative cholangiography (IOC)
during subsequent cholecystectomy which all negative for
CBD stones (Figure 1). During a 6-month follow-up period of
the 321 patients who did not undergo an ERCP, nine patients
were readmitted with right upper quadrant pain and elevated
liver tests which later normalised with no CBD stone demon-
strated, three patients were readmitted with presumed gall-
stone pancreatitis without a CBD stone being identified and
two patients were readmitted with cholecystitis. However, in
none of these 15 patients ERCP was required and all recov-
ered clinically, the two last mentioned patients underwent
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cholecystectomy. Two patients with residency outside Iceland
were lost to follow-up.
The negative predictive value (NPV) of MRCP was found to
be 93% and a normal MRCP investigation gave a 89% prob-
ability of having no CBD stone as well as no readmission due
to gallstone disease in the following 6 months. PPV, sensitiv-
ity and specificity of MRCP for CBD stones were found to be
80, 76, and 94%, respectively.
When selecting only patients who had an ERCP within 48 h
from the MRCP investigation, the sensitivity improved and
the PPV, sensitivity and specificity were found to be 82, 84,
and 95%, respectively. If only patients who underwent ERCP
within 24 h were included, only a minor improvement on
MRCPs’ sensitivity and specificity was observed (making the
sensitivity 86% and the specificity 96%). Excluding patients
who had a suboptimal MRCP investigation due to motion
artefacts or other technical issues (n¼ 44) did only slightly
improve the sensitivity of MRCP, from 84% to 85%.
In the analysis of patients with a normal MRCP and a
negative ERCP for CBD stones 24 ERCP investigations were
normal, five showed biliary sludge or raised suspicion of
stone disease and 13 demonstrated other pathology such as
post-operative bile leak, bile duct dilatation and/or papillary
stenosis (Figure 1). For the sub-group of patients (n¼ 78) who
had a normal MRCP undergoing an ERCP (n¼ 71)
investigation or IOC (n¼ 7), the NPV of MRCP was found to
be 63%. Comparing those who had a stone on ERCP (n¼ 29)
versus those who did not, either on ERCP or IOC (n¼ 49),
those with a demonstrable stone had lower CRP values, 34
(55) versus 77 (116) (p¼ 0.032), a higher proportion of gall-
bladder stones on MRCP, 18 (100%) versus 20 (65%) patients
(p¼ 0.004), and a shorter time in hospital, 3.9 (2.2) versus 7.4
(11.5) days (p¼ 0.045). No significant difference was observed
in any of the other variables recorded.
Comparison of those who had a stone demonstrated on
MRCP (group 1) and those without a stone (group 2) in terms
of demographics, symptoms, laboratory values, and additional
results of MRCP is shown in Table 1. Patients who had a
stone demonstrated on MRCP had significantly higher ALP,
GGT, AST, ALT, and bilirubin levels, but significantly lower CRP
and similar lipase values. Patients with a CBD stone on MRCP
also had a wider common bile duct and a higher ratio of con-
comitant gallbladder stones (Table 1). Patients without a
stone on MRCP had a lower proportion of jaundice and a
similar proportion of pancreatitis. After exclusion of patients
who were later suspected of alcohol induced pancreatitis
(n¼ 13), the difference in the proportion of pancreatitis
between the two groups remained unsignificant.
A comparison of patients with a normal MRCP who on
subsequent ERCP were found to have CBD stones (n¼ 29)
Figure 1. Flow chart, exclusion of patients and fate of patients following MRCP. *Other abnormal result of MRCP included one or more of the following: CBD dilata-
tion, intrahepatic bile duct dilatation, pancreatic duct dilatation, pancreatitis. **All six intraoperative cholangiographies (IOC) were negative for CBD stones. ***Other
pathology on ERCP included post-operative bile leak, bile duct dilatation and papillary stenosis.
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versus those who had a normal MRCP and no stone disease
detected (n¼ 363) revealed that those who had a stone dem-
onstrated also had lower CRP, higher bilirubin and more often
had jaundice. Also, those with a stone had a higher propor-
tion of gallbladder stones (Table 2).
A logistic regression analysis was undertaken on all
patients who underwent the gold standard ERCP or IOC to
demonstrate possible predictors of CBD stones. Independent
predictors were found to be a negative MRCP for CBD stones,
a non-dilated CBD and an absent gallbladder stone (Table 3).
Less significant predictors were non-dilated intrahepatic bile
ducts, ALP value below 150 IU/L and a bilirubin value below
60 lmol/L. In the multivariate regression analysis, many com-
binations of independent predictors were found to be signifi-
cant (Table 4). Some independent predictors as well as a
combination of predictors showed a tendency towards signifi-
cance but were not included since no corrections were made
for multiple testing.
Discussion
The main results of the current study suggest that MRCP is
an important diagnostic tool for the exclusion of choledocho-
lithiasis with a high negative predictive value. Very few
patients were readmitted due to suspected gallstone disease
within six months following a normal MRCP and for none of
these ERCP were required. However, NPV declined in those
who were suspected of having CDL despite a normal MRCP
and underwent ERCP. Independent predictors of the absence
of CBD stones apart from MRCP were found to be a non-
dilated CBD, an absent gallbladder stone, non-dilated intrahe-
patic bile ducts, bilirubin and ALP. Patients who had a stone
demonstrated on MRCP had a wider CBD, a higher ratio of
concomitant gallbladder stones and significantly higher ALP,
GGT, AST, ALT, and bilirubin but lower CRP and similar lipase
levels. An absent gallbladder stone, either independent or
along with bilirubin or ALP, in combination with MRCP,
showed significant combined predictive value.
In previous studies, MRCP has been shown to have sensi-
tivity for demonstration of CBD stones ranging from 57% to
100%, specificity of 72–100%, positive predictive value (PPV)
of 87–100%, and a negative predictive value (NPV) of
50–100% in the diagnosis of choledocholithiasis.
[6,8,9,11,13,14,17–21] A recent meta-analysis of 25 studies on
the detection rate of CBD stones demonstrated an estimated
sensitivity of 90% and specificity of 95% for MRCP.[22] It must
be noted that many studies reporting low sensitivity and/or
NPV of MRCP are more than a decade old and might be out-
dated due to the technological advancements of MRCP in the
period following their publication.[4,23,24] However, two
recent studies have not demonstrated high NPV of a negative
MRCP to exclude CDL.[13,17]
In clinical practise, it is of major importance to exclude
CBD stones in order to avoid unnecessary ERCPs.[6,21] Thus,
the clinical problem we wanted to address in the current
study was the reliability of a normal MRCP investigation for
Table 1. Patient characteristics.
Group 1a (n¼ 223) Group 2a (n¼ 697) p
Age, years
Mean (SD) 58 (22) 54 (20) 0.020
Range 18-100 13-97
Gender, n (%)
Men 83 (37%) 230 (33%) 0.256
Women 140 (63%) 467 (67%) 0.256
Clinical symptoms
Mean duration, days (SD) 4.7 (9.3) 4.0 (7.5) 0.345
Fever, n (%) 70 (32%) 226 (34%) 0.741
Laboratory values, mean (SD)
WBC (109/L) 10.0 (4.7) 10.3 (4.5) 0.400
CRP (mg/L) 59 (74) 77 (96) 0.006
ALP (IU/L) 271 (196) 204 (180) <0.001
Total bilirubin (lmol/L) 60 (51) 34 (35) <0.001
Bilirubin elevated, n (%) 160 (73%) 306 (47%) <0.001
GGT (IU/L) 501 (399) 341 (362) <0.001
AST (IU/L) 288 (274) 233 (276) 0.024
ALT (IU/L) 359 (326) 255 (285) <0.001
Amylase (IU/L) 413 (1021) 360 (738) 0.603
Lipase (IU/L) 2771 (8877) 3048 (7755) 0.697
Pancreatitisb, n (%) 39 (20%) 165 (27%) 0.058
Jaundicec, n (%) 106 (48%) 156 (24%) <0.001
MRCP findings, n (%)
CBD diameter, mm (SD) 9.72 (3.22) 7.93 (3.03) <0.001
Dilated CBD 139 (62%) 162 (23%) <0.001
Prior cholecystectomy 53 (24%) 191 (27%) 0.297
Cholecystitis 57 (33%) 197 (39%) 0.201
Gallbladder stone 148 (86%) 328 (65%) <0.001
aGroup 1 are the patients who had a CBD stone demonstrated on MRCP and group 2 patients who had no stone
identified on MRCP.
bBiochemical pancreatitis defined as a threefold elevation in lipase (> 900 IU/L).
cJaundice included patients with at least a twofold elevation in total bilirubin (> 50 lmol/L).
CRP: C-reactive protein; ALP: alkaline phosphatase; GGT: c-glutamyl transpeptidase; AST: aspartate aminotransferase;
ALT: alanine aminotransferase; CBD: common bile duct.
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the exclusion of common bile duct stones. Many factors are
known to contribute to the diagnostic challenges in sus-
pected CDL. A considerable proportion of CBD stones pass
spontaneously and thereafter do not seem to be clinically sig-
nificant.[25–27] The sensitivity of MRCP has also been shown
to be less for small stones (<5mm) and for stones lodged in
the ampulla of Vater as can occur during biliary
pancreatitis.[16,28,29]
Many studies analysing the overall diagnostic accuracy of
MRCP had a very limited number of participants
[5–9,11,13–21] with a range of 30 [5,8] to 315 patients.[11]
Many of these studies had a variety of different types of
patients and different and/or unclear definitions of a normal
or negative MRCP. In the current study, we investigated a
large number of patients with a clear definition of a normal
MRCP. Apart from the large number of patients included,
another strength of this study was the unique patient popula-
tion as our institution is the only hospital in the whole coun-
try of Iceland performing MRCP investigations and therefore
the missing data was minimal and only two patients with
residency outside Iceland were lost to follow-up.
The current study did have some limitations. A limitation
of this study as well as others of the same type is the some-
what subjective view of what might be considered a
CBD stone on MRCP reported by each radiologist. However,
this mirrors the situation in clinical practise and
Table 2. Normal MRCP (n¼ 392).
Group 1a (n¼ 29) Group 2a (n¼ 361) p
Age, years
Mean (SD) 47 (20) 50 (20) 0.486
Range 21-87 13-97
Gender, n (%)
Men 6 (21%) 113 (31%) 0.297
Women 23 (79%) 248 (69%) 0.297
Clinical symptoms
Mean duration, days (SD) 4.8 (6.2) 4.1 (7.9) 0.629
Fever, n (%) 6 (21%) 107 (30%) 0.300
Laboratory values, mean (SD)
WBC (109/L) 9.1 (3.4) 9.8 (4.1) 0.334
CRP (mg/L) 34 (55) 68 (94) 0.005
ALP (IU/L) 199 (87) 197 (167) 0.908
Total bilirubin (lmol/L) 56 (57) 32 (34) 0.038
Bilirubin elevated, n (%) 19 (66%) 151 (45%) 0.034
GGT (IU/L) 310 (228) 339 (359) 0.602
AST (IU/L) 233 (188) 246 (292) 0.755
ALT (IU/L) 310 (205) 264 (299) 0.279
Amylase (IU/L) 151 (275) 212 (444) 0.400
Lipase (IU/L) 1570 (3452) 1610 (4928) 0.957
Pancreatitisb, n (%) 5 (19%) 51 (16%) 0.783
Jaundicec, n (%) 14 (48%) 73 (22%) 0.002
MRCP findings, n (%)
CBD diameter, mm (SD) 6.87 (2.00) 6.02 (1.70) 0.135
Prior cholecystectomy 10 (34%) 99 (27%) 0.398
Cholecystitis 9 (53%) 107 (41%) 0.448
Gallbladder stone 18 (100%) 170 (65%) 0.001
Comparison between those who had a subsequent stone on ERCP and those who had no stone identified.
aGroup 1 are the patients who had a normal MRCP and a CBD stone demonstrated on ERCP and group 2
patients who had a normal MRCP and no stone identified. Two patients in group 2 were lost to follow-up.
bBiochemical pancreatitis defined as a threefold elevation in lipase (> 900 IU/L).
cJaundice included patients with at least a twofold elevation in total bilirubin (> 50lmol/L).
CRP: C-reactive protein; ALP: alkaline phosphatase; GGT: c-glutamyl transpeptidase; AST: aspartate aminotrans-
ferase; ALT: alanine aminotransferase; CBD: common bile duct.
Table 3. Independent predictors of the absence of CBD stones.
Predictor OR 95% CI p
neg. MRCPa 7.408 4.667–11.958 <0.001
neg. Gallbladder stoneb 3.546 1.870–6.867 <0.001
Non-dilated CBDb 2.194 1.435–3.379 <0.001
ALP <150 IU/L 1.706 1.082–2.691 0.021
Bilirubin <60 lmol/L 1.637 1.051–2.572 0.031
Non-dilated intrahep. ductsb 1.634 1.030–2.626 0.039
aNo CBD stone demonstrated on MRCP.
bAs diagnosed on MRCP.
Table 4. Combined predictors of the absence of CBD stones.
Model OR 95% CI p
1
neg. MRCPa 7.309 4.107–13.354 <0.001
neg. Gallbladder stone 3.118 1.480–6.707 0.003
ALP <150 IU/L 2.046 1.079–3.904 0.029
2
neg. MRCPa 8.135 4.474–15.284 <0.001
neg. Gallbladder stone 3.073 1.464–6.568 0.003
Bilirubin <50 lmol/L 1.906 1.041–3.556 0.039
3
neg. MRCPa 7.222 4.093–13.062 <0.001
neg. Gallbladder stone 3.331 1.626–6.973 0.001
4
neg. Gallbladder stone 3.348 1.742–6.562 <0.001
ALP <150 IU/L 2.066 1.173–3.645 0.012
5
neg. Gallbladder stone 3.314 1.727–6.484 <0.001
Non-dilated CBD 2.120 1.252–3.610 0.005
6
neg. Gallbladder stone 3.299 1.722–6.448 <0.001
Non-dilated intrahep. ducts 2.335 1.270–4.462 0.008
7
Non-dilated CBD 2.306 1.489–3.598 <0.001
Bilirubin <100lmol/L 2.437 1.155–5.644 0.026
aNo CBD stone demonstrated on MRCP.
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gastroenterologists performing ERCP procedures are also sub-
jects of subjective evaluation of cholangiograms. However, all
equivocal cases regarding the presence of CBD stones on an
MRCP were re-evaluated by an experienced radiologist and
also the equivocal cases on ERCP were reviewed retrospect-
ively by a surgeon with experience of ERCPs. Another import-
ant shortcoming owed to the fact that CBD stone size was
hugely underreported and could therefore not be recorded as
a variable in our study. Finally, investigators were not blinded
to the results of either MRCP or ERCP which could have had
an effect on their respective interpretation.
Negative predictive value and exclusion of
choledocholithiasis
The main results of the current study suggest that when CDL
is suspected MRCP has great excluding potential with a high
NPV, which is in line with many other studies.[6,7,9,11]
However, the NPV was found to be less for patients who sub-
sequently underwent ERCP based on evaluation of clinical
symptoms and biochemical parameters, a finding in concert
with recent observations.[13,17]
It must be noted that in many cases involving a high sus-
picion of CBD stones and a subsequent normal MRCP, there
is the potential for spontaneous passage of CBD stones. On a
similar basis, it is conceivable that some individuals with a
normal MRCP and a CBD stone shown on a subsequent ERCP
may theoretically have had a stone migration to the common
bile duct either spontaneously from the gallbladder or during
cholecystectomy after the MRCP had been undertaken. This is
supported by our observation, that a substantial amount of
false negative MRCPs result from extending the time-frame
between MRCP and ERCP beyond 48 h (seen as a reduction in
sensitivity), possibly allowing for stones to migrate from the
gallbladder. Among those with a normal MRCP, who had a
CBD stone demonstrated later on also had a significantly
higher proportion of gallbladder stones, making stone migra-
tion potentially more likely in those individuals. Thus, the true
NPV might be underestimated in our study, but it is also pos-
sible that all reported false negatives were truly false negative
MRCPs and that our estimation of the NPV is correct. In either
case, the NPV of MRCP is high.
PPV, sensitivity, and specificity
The sensitivity (76%) and PPV (80%) of MRCP were somewhat
lower than demonstrated in other studies while the specificity
was high and in keeping with other reported
data.[6,8,11,18,20,22] To better clarify these results, we
attempted to control for the possibility of previously men-
tioned stone passage through the ampulla of Vater and also
for stone migration from the gallbladder to the common bile
duct by considering only MRCPs followed by an ERCP within
48 h. This increased the sensitivity of MRCP whereas the PPV
remained lower than expected.[6,8,11,18,20]
Our results also suggest that minor motion or susceptibility
artefacts do not have a significant effect on the diagnostic
accuracy of MRCP with regard to CBD stones since excluding
suboptimal MRCPs did not affect the diagnostic accuracy of
MRCP markedly. Furthermore, narrowing the interval between
a diagnostic MRCP and a therapeutic ERCP further from the
aforementioned 48 h did not improve the diagnostic ability of
MRCP, since only a slight improvement in diagnostic accuracy
was observed in that sub-group of patients compared to the
group undergoing ERCP within 48 h.
Group comparison and the logistic model
A certain group of patients of interest were those who had a
normal MRCP undergoing an ERCP investigation. Those who
subsequently had a stone demonstrated on ERCP or IOC had
lower mean CRP and a shorter duration of hospital stay pos-
sibly indicating the effect of immediate therapeutic interven-
tion. A significant proportion of patients who had no stones
demonstrated were found to have a post-operative bile leak
possibly contributing to higher CRP values and longer hospital
stay. We found no clinically significant factors that could fur-
ther differentiate the two groups other than a higher propor-
tion of gallbladder stones, and so the more precise selection of
those truly warranting an ERCP after a normal MRCP is lacking.
In the overall comparison of those who had a stone on
MRCP versus those who did not, the observed difference in
cholestatic parameters such as bilirubin and ALP as well as
other liver tests such as AST and ALT was to be expected.
Also, jaundice was more common in those diagnosed with a
stone on MRCP. No difference was observed in the proportion
of pancreatitis between the two groups, which was an inter-
esting finding, and their lipase levels did not differ signifi-
cantly. These results suggest that a substantial amount of
patients undergoing MRCP for suspected CDL have already
had CBD stones pass through the ampulla of Vater and sup-
port previous findings showing a significant proportion of
CBD stones pass after pancreatitis, biliary colic, and cholecyst-
itis but less commonly after jaundice.[26]
Logistic regression analysis revealed that findings on MRCP
such as the absence of a CBD stone, a non-dilated bile duct
or the absence of a gallbladder stone were unsurprisingly the
best and most significant independent predictors for the
absence of CBD stones. An important finding was a combined
value of predictive capacity when adding the presence or
absence of a gallbladder stone and either ALP or bilirubin
together with MRCP alone, enhancing the excluding capacity
of MRCP.
Alkaline phosphatase (ALP)< 150 IU/L and bilirubin
<60 lmol/L were found to have independent predictive value
for excluding CBD stones, a finding consistent with other
reports.[11,30] However, in studies assessing the predictive
value of biochemical markers for CBD stones after logistic
regression, the markers showing predictive value commonly
vary.[11,30–32] This inevitably undermines the results of any
study attempting to identify these potential predictive factors.
Future implications
Considering the high NPV of MRCP in our study it is likely
that a considerable number of future patients could be
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spared an unnecessary ERCP, resulting both in a reduction of
adverse outcomes and the cost associated with the proced-
ure. Although a cost-benefit analysis was not performed and
the potential reduction of unnecessary ERCP procedures is
not fully quantified, our results provide a strong clue and
allow clinicians, making a decision regarding a possible ERCP,
to better rely on a negative MRCP.
Conclusion
Our results, based on a large number of subjects, show that a
normal MRCP has a very high negative predictive value and
very few patients are readmitted with CDL symptoms, with
no CBD stone demonstrated during a 6-month follow-up. This
supports the use of MRCP as a tool for exclusion of choledo-
cholithiasis with the potential to reduce the amount of
unnecessary ERCP procedures performed.
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